Curtis E. Haas, PharmD, FCCP, Pharmacy Times® Health-System Edition Editor in Chief

home / authors / curtis-e-haas-pharmd-fccp-pharmacy-times-health-system-edition-editor-in-chief

Articles

Most Favored Nation Pricing Is More Political Whitewash

Most Favored Nation Pricing Is More Political Whitewash

Curtis E. Haas, PharmD, FCCP, Pharmacy Times® Health-System Edition Editor in Chief
January 19th 2021

Health systems get just 36 days to make major administrative, information system, and operational changes amid the pandemic’s peak.

Read More

BYO Is Not a Good Idea for Pharmaceuticals

BYO Is Not a Good Idea for Pharmaceuticals

Curtis E. Haas, PharmD, FCCP, Pharmacy Times® Health-System Edition Editor in Chief
September 11th 2019

Health-System Leadership Should Develop Institutional Policy Forbidding the Acceptance of Drugs From an Outside Pharmacy

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD